// App-Quantinova.ai

SAT-0991 : Dapagliflozin Reduces HbA1c and Systolic Blood Pressure in Patients with Type 2 Diabetes: Subgroup Analysis Based on Patient Characteristics

Researchers

Presenter

  • Michael A Weber

Principal Investigators

  • Traci A Mansfield

  • James F List

  • Agata Ptaszynska

Medical Centers

  • SUNY Downstate College of Medicine, Brooklyn, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Type 2 diabetes mellitus

  • Hypertension

  • Diabetes

Biomarkers

  • GC Vitamin D Binding Protein

  • Hemoglobin A1c

  • Sex hormone binding globulin

  • Stromal interaction molecule 1

  • Uric acid levels

Drug/Treatment

  • Dapagliflozin

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved